CJC-1295 DAC 5mg

CJC-1295 with DAC

• Form: Lyophilized powder
• Purity: >99%

Overview

CJC-1295 with DAC is a synthetic 29–amino acid analog of growth hormone–releasing hormone (GHRH). It functions as a long-acting GHRH analog designed to stimulate the release of growth hormone (GH) from the pituitary gland. By incorporating a Drug Affinity Complex (DAC), this version was developed to extend half-life while maintaining receptor affinity.

Research Background

CJC-1295 with DAC is a modified fragment of GHRH with four substituted amino acids that improve stability and pharmacokinetics. The addition of the DAC component further extends its biological activity. DAC achieves this by binding to plasma proteins through a lysine derivative (N-epsilon-3-maleimidopropionamide) at the C-terminus. This modification increases the half-life to approximately 8 days compared to the shorter duration of CJC-1295 without DAC.

Despite its prolonged half-life, CJC-1295 with DAC retains significant affinity for GHRH receptors, similar to the non-DAC version. Researchers continue to explore its potential in stimulating GH release as well as in combination protocols (e.g., with Ipamorelin) for possible synergistic responses.

Mechanism of Interest

• Extended half-life: DAC modification allows binding to plasma proteins, prolonging biological activity.
• Receptor affinity: Retains strong binding to GHRH receptors on somatotroph cells in the pituitary gland.
• Growth hormone release: May promote GH secretion through GHRH receptor activation and downstream signaling.
• Synergistic potential: Studied in blends with ghrelin receptor activators (e.g., Ipamorelin) for enhanced GH response.

Molecular Information

• Molecular Formula: C152H252N44O42
• Molecular Weight: 3367.95 g/mol
• Other Names: CJC-1295, CJC-1295 with DAC, DAC:GRF, long-acting GHRH analog, tetrasubstituted GRF 1-29 with DAC